Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer.

ABSTRACT:

Background

Docetaxel is the only FDA-approved first-line treatment for castration-resistant prostate cancer (CRPC) patients. Docetaxel treatment inevitably leads to tumour recurrence after an initial therapeutic response with generation of multinucleated polyploid (MP) cells. Here we investigated role of MP cells in clinical relapse of CRPC.

Methods

Prostate cancer (PC-3) cells were treated with docetaxel (5 nM) for 3 days followed by a washout and samples were collected at close intervals over 35 days post drug washout. The tumorigenic potential of the giant MP cells was studied by implanting MP cells subcutaneously as tumour xenografts in nude mice.

Results

Docetaxel-induced polyploid cells undergo mitotic slippage and eventually spawn mononucleated cells via asymme

SUBMITTER: Mittal K 

PROVIDER: S-EPMC5418452 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature